Can base editing treat common diseases, not just rare ones?
Yes, and the shift is already underway. A 2023 study in nonhuman primates showed that a single intravenous dose of a CRISPR base-editing medicine (VERVE-101) targeting the PCSK9 gene lowered blood PCSK9 protein by 83% and LDL cholesterol by 69%, with effects lasting up to 476 days [2]. This therapy is now in human trials for heterozygous familial hypercholesterolemia—a condition that, while genetic, affects roughly 1 in 250 people, making it far more common than most rare diseases. Similarly, a 2023 study demonstrated that base editing could protect the heart from ischemia/reperfusion injury by editing the CaMKIIδ gene in mice, a strategy that could apply to the millions of patients who suffer heart attacks [5]. These examples show that base editing is not inherently limited to tiny patient populations; the same tool can be aimed at genes that drive widespread disease.
What makes scaling possible—and what still blocks it?
However, scaling still faces real hurdles. A 2026 systematic review of gene therapy for sickle cell disease—including base editing—found that while short-term outcomes are impressive (100% resolution of severe vaso-occlusive events in one pivotal cohort), successful delivery depends on a complex chain of steps: transfusion preparation, stem cell mobilization, apheresis collection, ex vivo manufacturing, conditioning chemotherapy, and reinfusion [4]. Each step introduces potential failure points and cost. The review also noted that long-term safety, fertility outcomes, and global scalability remain unresolved [4]. So while the platform approach is promising, the full treatment package—not just the editing itself—must become simpler and cheaper for base editing to reach large populations.
Can base editing handle multiple genes at once, and does that help scaling?
Personalization is also becoming more practical. A 2026 study on congenital heart defects found that CRISPR-based approaches—including base editing—achieved mutation correction rates of 72–88% with low off-target effects (1.5–6%), and that personalized strategies like patient-specific guide RNAs and AI-assisted targeting led to a 30–40% increase in survival and 55–65% reduction in symptoms [1]. While this study was quantitative and statistically significant, it drew on clinical trials and lab experiments rather than a single large trial, so the results should be seen as proof-of-concept rather than definitive. Still, it shows that the same base editing platform can be tailored to many different mutations without redesigning the entire therapy.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2023 to 2026, 3 from 2024 or later, 2 in Q1 journals, collectively cited 110 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 75 papers retrieved from a database of over 500 million.
Sources used in this answer
CRISPR-Assisted Genome Modification For Individualized Therapy Of Congenital Heart Defects: Innovations, Treatment Potential, And Clinical Significance
In a quantitative study of CRISPR-based therapies for congenital heart defects, base editing achieved 72–88% mutation correction rates with 1.5–6% off-target effects, and personalized approaches improved survival by 30–40% and reduced symptoms by 55–65% [1].
Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting
In nonhuman primates, a single intravenous dose of the base-editing medicine VERVE-101 lowered blood PCSK9 protein by 83% and LDL cholesterol by 69%, with effects lasting up to 476 days, supporting a first-in-human trial for familial hypercholesterolemia [2].
Advancing gene-editing platforms to improve the viability of rare-disease therapeutics: key insights from a 2024 Scientific Exchange hosted by ARM, ISCT, and Danaher
A 2024 multi-stakeholder exchange identified four platform elements (consistent delivery, manufacturing, quality requirements, and trial designs) that could yield up to fivefold efficiency gains and reduce time to dose patients from years to six months [3].
Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials.
A 2026 systematic review of autologous gene therapy for sickle cell disease (including base editing) found 100% resolution of severe vaso-occlusive events in one pivotal cohort, but noted unresolved barriers in long-term safety, fertility, and global scalability [5].
Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease
In a 2023 study, base editing of the CaMKIIδ gene in mice protected the heart from ischemia/reperfusion injury, suggesting a strategy applicable to broad populations with heart disease [9].